13F filer · CIK 1346824
RA CAPITAL MANAGEMENT, L.P.
BOSTON, MA · filing since Q2 2013 · last filing Aug 14, 2026
Reported value
$11.5B
+$2.1B vs prior
Positions
84
New / sold out
17 / 18
Added / reduced
10 / 10
Turnover
33.1%
buys $4.7B · sells $3.5B
Top-10 weight
60.4%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | ASCENDIS PHARMA A/S | +10,281,496 | – | +$2.7B |
| New | PARABILIS MEDICINES INC | +28,933,371 | – | +$791.9M |
| New | HEMAB THERAPEUTICS HOLDINGS | +7,808,627 | – | +$286.8M |
| New | ABIVAX SA-ADR | +1,132,557 | – | +$150.9M |
| New | ORUKA THERAPEUTICS INC | +1,554,597 | – | +$148.0M |
| Added | ARTIVA BIOTHERAPEUTICS INC | +8,102,340 | +82.2% | +$78.6M |
| New | INTELLIA THERAPEUTICS INC | +4,526,926 | – | +$76.6M |
| New | DEFINIUM THERAPEUTICS INC | +1,500,000 | – | +$70.6M |
| New | SANA BIOTECHNOLOGY INC | +18,750,000 | – | +$65.4M |
| New | PRELUDE THERAPEUTICS INC | +6,475,882 | – | +$34.5M |
17 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | ASCENDIS PHARMA A/S - ADR | -10,281,496 | -100.0% | $-2.4B |
| Sold out | DIANTHUS THERAPEUTICS INC | -2,611,733 | -100.0% | $-219.2M |
| Reduced | NUVALENT INC-A | -1,287,689 | -50.8% | $-159.0M |
| Sold out | PRAXIS PRECISION MEDICINES I | -373,787 | -100.0% | $-120.4M |
| Sold out | SAREPTA THERAPEUTICS INC | -3,902,596 | -100.0% | $-84.9M |
| Reduced | EDGEWISE THERAPEUTICS INC | -2,035,707 | -19.5% | $-82.7M |
| Sold out | SPYRE THERAPEUTICS INC | -1,621,620 | -100.0% | $-81.8M |
| Reduced | VOR BIOPHARMA INC | -3,002,903 | -55.6% | $-55.3M |
| Sold out | FULCRUM THERAPEUTICS INC | -6,053,960 | -100.0% | $-46.4M |
| Sold out | OLEMA PHARMACEUTICALS INC | -2,600,000 | -100.0% | $-38.8M |
18 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | ASCENDIS PHARMA A/SCOMMON STOCK | 10,281,496 | $2.7B | 23.83% |
| 2 | PARABILIS MEDICINES INCCOMMON STOCK | 28,933,371 | $791.9M | 6.88% |
| 3 | RHYTHM PHARMACEUTICALS INCCOMMON STOCK | 6,666,837 | $740.2M | 6.43% |
| 4 | VAXCYTE INCCOMMON STOCK | 11,474,599 | $667.0M | 5.80% |
| 5 | SIONNA THERAPEUTICS INCCOMMON STOCK | 9,905,045 | $435.7M | 3.79% |
| 6 | TYRA BIOSCIENCES INCCOMMON STOCK | 12,198,625 | $389.6M | 3.39% |
| 7 | EDGEWISE THERAPEUTICS INCCOMMON STOCK | 8,392,730 | $341.0M | 2.96% |
| 8 | NEWAMSTERDAM PHARMA CO NVCOMMON STOCK | 9,550,191 | $323.7M | 2.81% |
| 9 | HEMAB THERAPEUTICS HOLDINGSCOMMON STOCK | 7,808,627 | $286.8M | 2.49% |
| 10 | SEPTERNA INCCOMMON STOCK | 6,995,858 | $234.3M | 2.04% |
74 more rows. Subscribe for $29/month to see every row, download the data and use the API.